ATX-GD-59

Immune In trials Human trials

A mix of two short peptides copied from the thyroid-stimulating hormone receptor. The idea is to retrain the immune system to tolerate that receptor, so it stops making the antibodies that drive Graves' disease, instead of suppressing immunity overall.

Why people take it

What studies report

• Fell antibody levels against the thyroid receptor in most participants of a small phase 1 study

Worth knowing: One small open-label study in 12 people; no control group.

Status: Early (phase 1) human study only. Not approved.

Route

Subcutaneous injection, from reconstituted lyophilised powder

Available as

1.6 mg

Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.